A 1-year-old with posterior polymorphous corneal dystrophy is one of the youngest patients ever to have a bilateral cornea transplant via Descemet’s membrane endothelial keratoplasty (DMEK).
Read MoreHow to Use Topical Losartan to Potentially Treat Cornea Damage
Topical losartan potentially can help reverse corneal scarring fibrosis caused by disease, injury and surgical complications. More clinical trials are needed to evaluate its efficacy and safety. The pioneering investigator, Steven E. Wilson, MD, offers guidance.
Exudative Stability Key to Anti-VEGF Outcome in nAMD
Stabilizing the volume of exudative fluid, including subretinal fluid, may help maximize anti-VEGF treatment outcomes for patients with nAMD.
Unlocking Precision Medicine in RVO: When Anti-VEGF Therapy Isn’t Effective
Although anti-VEGF therapy is the current gold-standard treatment for retinal vein occlusion, not all patients respond to it. A study has found that volume of intraretinal fluid, among other factors detectable with optical coherence tomography, may help predict treatment response.
Diabetic Macular Edema Can Take 1-2 Years to Resolve in Patients Despite Aggressive Treatment
Greater central subfield thickness and better visual acuity at baseline are associated with longer time to resolution of diabetic macular edema, shows study.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Long-Term Topical Dorzolamide Improves Visual Acuity in Juvenile X-Linked Retinoschisis
Patients with juvenile X-linked retinoschisis (XLRS) treated with daily topical dorzolamide have improved visual acuity even eight years later. The study has the longest follow-up to date in an XLRS case series.
‘Second Generation’ Brillouin Microscopy May Better Identify Patients for Refractive Surgery, Corneal Cross-Linking
A “second generation” of Brillouin microscopy may help ophthalmologists screen patients for refractive surgery, select surgical technique and identify patients who need corneal cross-linking.
Unlocking the Potential of OCT: From Imaging to Biomarker Discovery
The Cole Eye Institute’s Justis P. Ehlers, MD, has helped unlock the potential of optical coherence tomography (OCT), using it to discover new biomarkers that may enhance precision medicine. The American Society of Retina Specialists and the Macula Society recently honored him with their Young Investigator Awards.
Don’t Miss These Cole Eye Institute Experts at AAO 2022
See Cole Eye Institute experts at Booth 3254 at the American Academy of Ophthalmology’s annual meeting to learn about the latest in research and clinical care, from corneal biomechanics to uveitis to intraocular tumors.
Hypertension Drug Losartan Reverses Scarring and Restores Vision After Cornea Damage
One of the most common medications for hypertension also may treat cornea damage, able to reverse corneal scarring and restore vision — potentially even in patients with eye injuries and diseases that occurred years ago.
DAVIO Trial Results: Vorolanib Injection Reduces Treatment Burden for Patients with nAMD
Standard treatment for nAMD involves repeated anti-VEGF injections. A recent study has found that an investigational therapy, administered through a bioerodible insert in the vitreous cavity, reduced treatment burden by 74% in one year.